Daniel GeffkenInterim Chief Financial Officer
Daniel Geffken has served as our Interim Chief Financial Officer since August 2015. Mr. Geffken is a founder and managing director at Danforth Advisors, LLC, a management consulting firm, where he has served since 2011. Previously, he served as chief operating officer of Seaside Therapeutics, Inc., a biotechnology company focused on neurodevelopmental disorders, from 2009 to 2011. In addition, prior to Seaside Therapeutics, Mr. Geffken previously served as chief operating officer or chief financial officer of several publicly traded and privately held companies, including Transkaryotic Therapies, Inc. and CytoTherapeutics, Inc. and as a principal of Signal Capital, Inc., a private equity firm. Mr. Geffken received his M.B.A from the Harvard Business School and his B.S. in economics from The Wharton School, University of Pennsylvania.